Document Detail

Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy.
MedLine Citation:
PMID:  17668319     Owner:  NLM     Status:  MEDLINE    
In the past few years, the dogma that the heart is a terminally differentiated organ has been challenged. Evidence from preclinical investigations emerged that there are cells, even in the heart itself, that may be able to restore impaired cardiac function after myocardial infarction. Although the exact mechanisms by which the infarcted heart can be repaired by stem cells are not yet fully defined, there is a new optimism among cardiologists that this treatment will prove successful in addressing the cause of heart failure after myocardial infarction-myocyte loss. Despite the promising preliminary data of human myocardial stem cell trials, scientists have also focused on the possibility of enhancing the underlying mechanisms of stem cell repair to gain healthier myocardial tissue. Attempts to induce neo-angiogenesis by transfecting stem cells with signaling factors (such as VEGF), to raise the number of endothelial progenitor cells with medical treatments (such as statins), to transfect stem cells with heat shock protein 70 (as a cardioprotective agent against ischemia) and to enhance the healing process after myocardial infarction with the use of various forms of stimulating factors (G-CSF, SCF, GM-CSF) have been made with notable results. In this article, we summarize the evidence from preclinical and clinical myocardial stem cell studies that have addressed the possibility of enhancing the regenerative capacity of cells used after myocardial infarction.
Marton Vertesaljai; Zsolt Piroth; Geza Fontos; Gyorgy Andreka; Gusztav Font; Gergely Szantho; Sandor Lueff; Marienn Reti; Tamas Masszi; Laszlo Ablonczy; Eszter D Juhasz; Tamas Simor; Mark S Turner; Peter Andreka
Related Documents :
18457469 - Acadesine: aica riboside, ara 100, arasine, gp 1 110.
4073219 - Myocyte vacuolization in infarct border zones is reversible.
16771749 - Acute segmental testicular infarction.
20096279 - Epigenetic control of cardiomyocyte production in response to a stress during the medak...
12226479 - Hypoxia and acidosis activate cardiac myocyte death through the bcl-2 family protein bn...
19215239 - Hepatocyte growth factor plays a critical role in the regulation of cytokine production...
15968959 - Quantitative changes in mast cell populations after left ventricular assist device impl...
24559419 - Cardiac arrhythmias the first month after acute traumatic spinal cord injury.
17056829 - Dose of aspirin in the treatment and prevention of cardiovascular disease: current and ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2007-08-01
Journal Detail:
Title:  Heart failure reviews     Volume:  13     ISSN:  1382-4147     ISO Abbreviation:  Heart Fail Rev     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-03-25     Completed Date:  2008-08-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9612481     Medline TA:  Heart Fail Rev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  227-44     Citation Subset:  IM    
Department of Adult Cardiology, Gottsegen Hungarian Institute of Cardiology, Haller u. 29, Budapest 1096, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Agents / therapeutic use*
Gene Transfer Techniques*
Heart Failure / therapy*
Myocardial Infarction / therapy*
Point-of-Care Systems*
Stem Cell Transplantation / methods*
Treatment Outcome
Reg. No./Substance:
0/Cardiovascular Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Production of TNF-alpha, IL-1beta, IL-12 and IFN-gamma in murine peritoneal macrophages on treatment...
Next Document:  Screening, diagnosis & monitoring of depression/distress in CHF patients.